Inclisiran
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Dec 16, 2024 → Feb 1, 2027
NCT ID
NCT06249165About Inclisiran
Inclisiran is a approved stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06249165. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06249165 | Approved | Active |
| NCT06386419 | Approved | Active |
| NCT05682378 | Phase 3 | Active |
| NCT04929249 | Phase 3 | Completed |
| NCT04873934 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease